HAL (France)open access
Concomitant mutation status of ALK-rearranged non-small cell lung cancers and its prognostic impact on patients treated with crizotinib
Crizotinib, ALK fusion, Concomitant mutation, Non-small cell lung cancer NSCLC, Anaplastic lymphoma kinase rearrangement ALK rearrangement, 0, Next-generation sequencing NGS
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 1000753
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.